このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

高リスク慢性骨髄単球性白血病(AVENHIR)患者におけるアザシチジンとベネトクラクスの併用 (AVENHIR)

2026年9月24日 更新者:Groupe Francophone des Myelodysplasies

高リスクの慢性骨髄単球性白血病(CMML)患者におけるベネトクラクス(VEN)と組み合わせたアザシチジン(AZA)の安全性導入による第II相試験

Open-label phase II, single arm, multicenter study with safety run-in to evaluate the efficacy and safety of Azacitidine combined with Venetoclax in patients with higher-risk chronic myelomonocytic leukemia

調査の概要

状態

積極的、募集していない

介入・治療

詳細な説明

AVENHIR trial is an open-label phase II, single arm, multicenter study with safety run-in to evaluate the efficacy and safety of the combination of Azacitidine and Venetoclax in, hypomethylating agent-naïve, higher-risk chronic myelomonocytic leukemia patients

研究の種類

介入

入学 (推定)

44

段階

  • フェーズ2

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究場所

      • Amiens、フランス、80054
        • CHU d'Amiens
      • Angers、フランス、49033
        • CHU d'Angers
      • Bobigny、フランス、93009
        • Hôpital Avicenne
      • Cesson-Sévigné、フランス、35510
        • Hôpital privé Sévigné
      • Grenoble、フランス、38043
        • CHU de Grenoble
      • Lille、フランス、59037
        • Hôpital Claude Huriez
      • Limoges、フランス、87046
        • CHRU de Limoges
      • Mont-de-Marsan、フランス、40000
        • Centre Hospitalier de Mont de Marsan
      • Montpellier、フランス、34295
        • CHU de Montpellier - Hôpital Saint Eloi
      • Nantes、フランス、44093
        • CHU Hôtel Dieu
      • Nantes、フランス、44277
        • Hôpital privé du Confluent SAS
      • Nice、フランス、06200
        • Hôpital Archet 1
      • Paris、フランス、75014
        • Hôpital Cochin
      • Paris、フランス、75010
        • Hôpital Saint Louis
      • Pessac、フランス、33604
        • CHU de Bordeaux - Hôpital Haut-Lévêque
      • Pierre-Bénite、フランス、69495
        • Centre hospitalier Lyon sud
      • Poitiers、フランス、86021
        • CHU de Poitiers
      • Pontoise、フランス、95300
        • Hôpital NOVO
      • Pringy、フランス、74374
        • Centre Hospitalier Annecy Genevois - Site d'Annecy
      • Rennes、フランス、35033
        • Hôpital Pontchaillou
      • Rouen、フランス、76038
        • Centre Henri Becquerel
      • Toulouse、フランス、31059
        • IUCT oncopole
      • Tours、フランス、37000
        • CHU de Tours - Hôpital Bretonneau
      • Villejuif、フランス、94800
        • Institut Gustave Roussy

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

18年歳以上 (大人、高齢者)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

説明

Inclusion Criteria:

  1. Age 18 and older.

  2. CMML diagnosis according to ICC 2022 criteria.

  3. Intermediate-2 or high risk according to the molecular CMML Prognostic Scoring System (CPSS-mol) at study entry. In patients treated with HY at screening, the white blood count (WBC) prior to introduction of HY will be used to compute CPSS-mol. In patients with failed or missing cytogenetics or genetics at screening, cytogenetics and genetics at CMML diagnosis will be used to compute CPSS-mol.

  4. No prior treatment with hypomethylaing agents, including Azacitidine, decitabine, SGI-110, AST7227 or CC-486 for CMML or any antecedent condition, including antecedent MDS or auto-immune disease. Prior treatment with Erythropoiesis Stimulating Agents (ESA) is allowed with a > 15 days washout from ESAs. Prior treatment with hydroxyurea (HY) is acceptable. No washout is necessary for those patients but pre-HY WBC will be taken in consideration for CPSS-mol computation.

  5. Performance status 0-2 on the Eastern Cooperative Oncology Group (ECOG) Scale.

  6. Adequate organ function including the following:

    • total bilirubin < 2 times upper limit of normal (ULN) (except moderate unconjugated hyperbilirubinemia due to intra medullary hemolysis or due to Gilbert syndrome),
    • alanine transaminase (ALT) and aspartate transaminase (AST) < 3 times ULN,
    • Creatinine clearance > 30 mL/min as estimated by the CKD-EPI equation.
  7. Signed Informed Consent Form (ICF).

  8. Negative pregnancy and adequate contraception (including in male patients) if relevant.

    A FCBP (female of childbearing potential) for this study is defined as a sexually mature woman who: (1) has not undergone a hysterectomy or bilateral oophorectomy; or (2) has not been naturally postmenopausal (amenorrhea following cancer therapy does not rule out childbearing potential) for at least 24 consecutive months (ie, has had menses at any time in the preceding 24 consecutive months).

    A FCBP participating in the study must:

    • Have had 2 negative pregnancy tests as verified by the investigator prior to starting investigational medicinal product (IMP) (unless the screening pregnancy test was done within 72 hours of Cycle 1 Day 1). She must have had agreed to ongoing pregnancy testing during the course of the study and after end of treatment.

    • If sexually active, agree to use, and be able to comply with, highly effective contraception** without interruption, 5 weeks prior to starting IMP, during treatment with IMP (including dose interruptions), and for 3 months after the last dose of IMP.

      • Highly effective contraception is defined in this protocol as the following (information also appears in the ICF): Hormonal contraception (eg, birth control pills, injection, implant, transdermal patch, vaginal ring), intrauterine device, tubal ligation (tying your tubes), or a partner with a vasectomy.

    Male subjects must have agreed to use a condom, defined as a male latex condom or nonlatex condom NOT made out of natural (animal) membrane (eg, polyurethane), during sexual contact with a pregnant female or a FCBP while participating in the study, during dose interruptions, and for at least 3 months after the last dose of IMP, even if he had undergone a successful vasectomy.

  9. Affiliation to a health insurance system.

Exclusion Criteria:

  1. Myeloproliferative / myelodysplastic syndrome other than CMML.
  2. Bone marrow or peripheral blood blasts (including promonocytes) ≥ 20%. If both local and central review are available and discrepant, the central review will be used.
  3. CMML with t(5;12) or PDGFRbeta rearrangement that may be treated with imatinib.
  4. Unavailable CPSS-mol at inclusion (WBC prior to HY used to compute CPSS-mol at inclusion in HY-exposed patients) or with a CPSS-mol low or intermediate-1 at study entry.
  5. Pregnant or breastfeeding.
  6. Serious concomitant systemic disorder, including auto-immune or auto-inflammatory disease requiring > 20 mg/d prednisone equivalent, active bacterial, fungal or viral infection that in the opinion of the investigator, would compromise the safety of the patient and/or his/her ability to complete the study.
  7. Medical condition requiring therapies with CYP3A strong or moderate inducing or inhibiting activity at screening. All strong or moderate CYP3A inducers should be discontinued 7 days prior to the first dose of study drug. All strong or moderate CYP3A inhibitors should be discontinued 3 days prior to the first dose of study drug. A sample list of CYP3A4 inhibitors and inducers is provided in Appendix F.
  8. Prior malignancy (except in situ cervix carcinoma, limited basal cell carcinoma, asymptomatic prostatic cancer not requiring treatment, or other tumors if not active during the last 2 years).
  9. Known positive test for human immunodeficiency virus (HIV). Note that HIV testing is not required at Screening.
  10. Malabsorption syndrome or other condition that precludes an enteral route of administration.
  11. Previous therapy with a hypomethylating agent including azacitidine, decitabine, SGI-110, AST7227 or CC-486 for CMML or any antecedent condition, including antecedent MDS or auto-immune disease.
  12. Previous therapy with a BH3 mimetic.
  13. Antecedent allogeneic stem cell transplantation (HSCT) for CMML or an antecedent of hematological malignancy. Those never transplanted but eligible for HSCT are eligible for the trial.
  14. Subjects referred to in Articles L1121-5 to L1121-8-1 and L1122-1-2 of the Public Health Code.

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:処理
  • 割り当て:なし
  • 介入モデル:単一グループの割り当て
  • マスキング:なし(オープンラベル)

武器と介入

参加者グループ / アーム
介入・治療
実験的:Azacidine+Venetoclax

Azacitidine will be administered subcutaneously at the standard dose of 75 mg/m²/d either on days 1-7 or using a 5-2-2 schedule of the 28 day-cycles.

Patiens will be exposed to Venetoclax during the first 7 or 14 days of the 28 day-cycles (number of days of Venetoclax determined during the safety run-in phase).

At cycle 1, Venetoclax will be given orally with 3-day ramp-up, at 100 mg on day 1, 200 mg on day 2 and 400 mg on days 3 to 7 or 14 of the cycle.

At all subsequent cycles, Venetoclax will be given orally at 400 mg on days 1 to 7 or 14 of the cycle.

Treatment duration will be 24 months.

Combination of Azacitidine and Venetoclax

他の名前:
  • ABT-199

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Safety run-in
時間枠:after 2 cycles of treatment of the safety run-in phase patients (each cycle is 28 days)

Determination of dose-limiting toxicities within the first two cycles of treatment

after 2 cycles of treatment of the safety run-in phase patients (each cycle is 28 days)
Overall response rate
時間枠:after 3 and 6 cycles of treatment of the phase II patients (each cycle is 28 days)

Overall response encompasses complete remission, partial remission, marrow response and clinical benefit according to protocol-defined criteria modified from MDS/MPN IWG criteria after 3 and 6 cycles of treatment

after 3 and 6 cycles of treatment of the phase II patients (each cycle is 28 days)

二次結果の測定

結果測定
メジャーの説明
時間枠
Complete remission rate
時間枠:after 3 and 6 cycles of treatment (each cycle is 28 days)

Complete remission according to protocol-defined criteria modified from MDS/MPN IWG criteria after 3 and 6 cycles of treatment

after 3 and 6 cycles of treatment (each cycle is 28 days)
Overall response rate at best response
時間枠:through study completion, an average of 5 years

Overall response (complete remission, partial remission, marrow response, clinical benefit) according to protocol-defined criteria modified from MDS/MPN IWG criteria at best response

through study completion, an average of 5 years
Overall response rate after 3 and 6 cycles of treatment
時間枠:after 3 and 6 cycles of treatment (each cycle is 28 days)

Overall response (complete remission, partial remission, marrow response, clinical benefit) according to the DACOTA trial response criteria after 3 and 6 cycles of treatment

after 3 and 6 cycles of treatment (each cycle is 28 days)
Duration of response
時間枠:through study completion, an average of 5 years

Duration of response defined as the time interval between the first date of achievement of any response according to MDS/MPN IWG criteria to progressive disease

through study completion, an average of 5 years
Identification and grading of adverse events
時間枠:through study completion, an average of 5 years

Safety profile, both hematological and non-hematological of treatment (Venetoclax combined with Azacitidine) including identification and grading of adverse events based on NCI CTCAE version 5.0

through study completion, an average of 5 years
Overall survival
時間枠:through study completion, an average of 5 years

Overall survival defined as the time from inclusion until death or end of follow-up

through study completion, an average of 5 years
Acute Myeloid Leukemia (AML)-free survival
時間枠:through study completion, an average of 5 years

AML-free survival defined as the time from inclusion to transformation to AML according to WHO 2016 criteria, death or end of follow-up, whichever occurs first

through study completion, an average of 5 years
Progression-free survival
時間枠:through study completion, an average of 5 years

Progression-free survival defined as the time from inclusion to progressive disease according to MDS/MPN IWG criteria, transformation to AML, death or end of follow-up, whichever occurs first

through study completion, an average of 5 years
Event-free survival
時間枠:through study completion, an average of 5 years

Event-free survival defined as the time from inclusion to failure to achieve any response according to MDS/MPN IWG criteria at the 6-cycle evaluation, occurence of progressive disease according to MDS/MPN IWG criteria, transformaion to AML, or death, whichever occurs first

through study completion, an average of 5 years
Cumulative incidence of AML and cumulative risk of death without AML
時間枠:through study completion, an average of 5 years

Cumulative incidence of AML and cumulative risk of death without AML, considering death and transformation to AML as competing risk

through study completion, an average of 5 years
Cumulative incidence of progressive disease or transformation to AML and cumulative risk of death without progression or AML
時間枠:through study completion, an average of 5 years

Cumulative incidence of progressive disease or transformation to AML and cumulative risk of death without progression or AML

through study completion, an average of 5 years
Rate of Hematopoietic Stem Cell Transplantation (HSCT)
時間枠:through study completion, an average of 5 years

Rate of Hematopoietic Stem Cell Transplantation (HSCT) and post-HSCT ovrall survival and AML-free survival

through study completion, an average of 5 years
Survival censoring at Hematopoietic Stem Cell Transplantation (HSCT)
時間枠:through study completion, an average of 5 years

Overall survival, AML-free survival and progressive-free survival censoring at Hematopoietic Stem Cell Transplantation (HSCT)

through study completion, an average of 5 years
Subsequent therapy
時間枠:through study completion, an average of 5 years

Rate and description of subsequent therapy

through study completion, an average of 5 years
Survival censoring to subsequent therapy
時間枠:through study completion, an average of 5 years

Overall survival, AML-free survival and progressive-free survival censoring at subsequent therapy

through study completion, an average of 5 years

その他の成果指標

結果測定
メジャーの説明
時間枠
Patient reported outcomes
時間枠:through study completion, an average of 5 years

Patient reported outcomes according to the Myeloproliferative Neoplasm Safety Assessment Form Total Symptom Score which is a 10-item instrument designed to monitor clinically relevant symptoms among patients with myeloproliferative neoplasm. The score has possible range of 0 to 100.

through study completion, an average of 5 years
Exploratory endpoints
時間枠:through study completion, an average of 5 years

Biomarkers including somatic mutations by targeted sequencing and BH3 profiling CD34+ cells and monocytes

through study completion, an average of 5 years

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

協力者

捜査官

  • 主任研究者:Raphaël ITZYKSON, MD/PhD、Hôpital Saint Louis
  • 主任研究者:Pierre FENAUX, MD/PhD、Hôpital Saint Louis

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2023年10月4日

一次修了 (実際)

2026年6月16日

研究の完了 (推定)

2028年10月1日

試験登録日

最初に提出

2023年2月23日

QC基準を満たした最初の提出物

2023年3月3日

最初の投稿 (実際)

2023年3月14日

学習記録の更新

投稿された最後の更新 (実際)

2026年9月29日

QC基準を満たした最後の更新が送信されました

2026年9月24日

最終確認日

2026年9月1日

詳しくは

本研究に関する用語

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

いいえ

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する